Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment
NCT06386874 · View on ClinicalTrials.gov ↗
Study Summary
This is a multicenter study that will be conducted at approximately 20 centers and up to 30 centers, if the sample size will be increased following interim assessment. The Q Therapeutic System (BQ 3.0) is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. The Q Therapeutic System (BQ 3.0) is indicated for adjunctive use in a clinical facility or home setting, in addition to standard-of-care therapies. * In Stage 1 (starting 4-21 days after the index stroke event to day 90 post stroke), participants will be randomly assigned (1:1) to receive either active or the sham treatments, up to 5 times a week, and at least to a total of 45 treatments. * In Stage 2 (day 90 to day 180 post stroke), participants in both the active and the control group will be allowed to continue to receive active treatments, up to 5 times per week. * In stage 3 (day 180 to day 270 post stroke), participants will not receive any treatments and would be followed up until the final visit at day 270. Each session will last approximately 60 minutes, with stimulation activated for up to 40 minutes, in conjunction with a home-based exercise program. Treatments may be administered in the hospital, in the clinic or in a home setting. The study will enroll 100-122 adult subjects who will be randomly assigned (1:1 allocation ratio) to either active or sham study intervention using the BQ 3.0 system.
Conditions Studied
Interventions
- DEVICE Q Therapeutic System (BQ 3.0) - Active
- DEVICE Q Therapeutic System (BQ 3.0) - Sham
Study Locations (14)
New Jersey
- Hackensack Meridian JFK Johnson Rehabilitation Institute — Edison
- Kessler Foundation for Rehabilitation — West Orange
New York
- New York-Presbyterian Brooklyn Methodist Hospital Inpatient Rehabilitation Unit — Brooklyn
- Burke Rehabilitation Hospital — White Plains
California
- Rancho Research Institute — Downey
District of Columbia
- MedStar National Rehabililtaion Hospital, — Washington D.C.
Florida
- Brooks Rehabilitation Hospital — Jacksonville
Georgia
- Emory University School of Medicine — Altanta
Illinois
- Shirley Ryan AbilityLab — Chicago
Kansas
- KUMC- KU Medical Center — Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2024-08-20 |
| Est. Completion | 2026-10 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06386874
The ClinicalTrials.gov registry entry for NCT06386874 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BrainQ Technologies, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions — of which Q Therapeutic System (BQ 3.0) - Active is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06386874 reports 14 study locations spanning 12 distinct geographic areas — top geographies include New Jersey, New York, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06386874 about?
NCT06386874 is a clinical study titled "EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment". This is a multicenter study that will be conducted at approximately 20 centers and up to 30 centers, if the sample size will be increased following interim assessment. The Q Therapeutic System (BQ 3.0) is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and...
What is the current status of trial NCT06386874?
This trial is currently recruiting. It is a NA study. The enrollment target is 122 participants. The study started on 2024-08-20. Estimated completion is 2026-10.
What conditions does trial NCT06386874 study?
This clinical trial studies the following conditions: Ischemic Stroke. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06386874?
The interventions under investigation include: Q Therapeutic System (BQ 3.0) - Active (DEVICE), Q Therapeutic System (BQ 3.0) - Sham (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06386874?
This trial is sponsored by BrainQ Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06386874 being conducted?
This trial has 14 study locations across California, District of Columbia, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.